New PET tracer shows promise for spotting early tumors
NCT ID NCT06471712
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This early-phase trial tested an experimental imaging agent called 18F-LNC1007 in 8 people—healthy volunteers and cancer patients with a small number of tumors. The goal was to see how the agent spreads through the body, how much radiation it gives off, and whether it is safe. Participants received one injection and underwent PET/CT scans over about a week.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Precision Molecular Imaging & Theranostics (trading as Melbourne Theranostic Innovation Centre)
Melbourne, Australia
Conditions
Explore the condition pages connected to this study.